Safety Reading Notes

Read safety context beside the research guide.

The TRPV1 cannabinoid target source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 30697147

PubMed For Dummies Article

TRPV1 cannabinoid target Evidence Review: the long-form source walk-through

Quick read
  • TRPV1 cannabinoid target currently has 18 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 30697147
  • The evidence classes most visible in the row language are insufficient (15), mechanistic or pharmacological (2), and preclinical (1). PMID 34259916
  • The study-design language most visible in the row language is Narrative or expert review (14), and Animal study (4). PMID 16596770
  • The repeated topics are TRPV1 (18), which tells the reader where to start opening PubMed and DOI links. PMID 40465624

Start with the research question

TRPV1 cannabinoid target is built from 18 source-backed evidence row(s) and 18 research source(s). The current evidence classes read as insufficient (15), mechanistic or pharmacological (2), and preclinical (1), and the study-design language most often reads as Narrative or expert review (14), and Animal study (4). PMID 30697147

The row-level question is not simply whether TRPV1 cannabinoid target is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are TRPV1 (18). PMID 37199723

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 16109430

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 21309120

Mechanistic evidence 2 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 17906678

Limits and uncertainty 15 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 37199723

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 26411767

Where this page has the most source density

The largest bucket surfaced for this page is TRPV1: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is TRPV1: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 30697147

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 37199723

Bucket chapters: what the literature is circling

TRPV1: insufficient

15 research sources 15 rows (971-988) Evidence class: insufficient

This bucket summarizes source-backed rows focused on TRPV1: insufficient. It currently draws from 15 research source(s), so the exact study type matters. PMID 30697147

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 30697147

  • Evidence row 971

    THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147

  • Evidence row 988

    THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31695229

TRPV1: mechanistic or pharmacological

2 research sources 2 rows (978, 982) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on TRPV1: mechanistic or pharmacological. It currently draws from 2 research source(s), so the exact study type matters. PMID 37199723

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 37199723

  • Evidence row 978

    CBD modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or phar... PMID 37199723

  • Evidence row 982

    Endocannabinoids modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signa... PMID 31408376

TRPV1: preclinical

1 research source 974 Evidence class: preclinical

This bucket summarizes source-backed rows focused on TRPV1: preclinical. It currently draws from 1 research source(s), so the exact study type matters. PMID 40465624

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 40465624

  • Evidence row 974

    Cannabinoids modulates TRPV1; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 40465624

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (2 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 30697147

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 37199723

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 36222019
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 32738201
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 31408376

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 30697147

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 37199723

Source-reading checklist for TRPV1 cannabinoid target

  1. Open the linked PubMed or DOI record. PMID 40684872
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 31839498
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 30194563
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 32091020
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 27179600

Source Notes

TRPV1 cannabinoid target source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 971

    THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
  2. Evidence row 972

    THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 34259916

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
  3. Evidence row 973

    THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 16596770

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
  4. Evidence row 974

    Cannabinoids modulates TRPV1; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 40465624

    Evidence class: preclinical; Study design: Animal study. Source: The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels.
  5. Evidence row 975

    Cannabinoids modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 16109430

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid signalling.
  6. Evidence row 976

    THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 21309120

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids and anxiety.
  7. Evidence row 977

    OEA modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 17906678

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Novel cannabinoid receptors.
  8. Evidence row 978

    CBD modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 37199723

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol sensitizes TRPV2 channels to activation by 2-APB.
  9. Evidence row 979

    Anandamide modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 26411767

    Evidence class: insufficient; Study design: Narrative or expert review. Source: TRPV1 Channel: A Potential Drug Target for Treating Epilepsy.
  10. Evidence row 980

    Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 36222019

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid signaling in microglia.
  11. Evidence row 981

    Cannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 32738201

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Modulation of TRPV1 channel function by natural products in the treatment of pain.
  12. Evidence row 982

    Endocannabinoids modulates TRPV1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31408376

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The TRPV1 channel regulates glucose metabolism.
  13. Evidence row 983

    CBD modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 40684872

    Evidence class: insufficient; Study design: Animal study. Source: Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.
  14. Evidence row 984

    THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31839498

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment.
  15. Evidence row 985

    THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30194563

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis for the Treatment of Epilepsy: an Update.
  16. Evidence row 986

    THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 32091020

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.
  17. Evidence row 987

    Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 27179600

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Beyond Cannabis: Plants and the Endocannabinoid System.
  18. Evidence row 988

    THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 31695229

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis y los sistemas exocannabinoide y endocannabinoide. Su uso y controversias.